Chargement en cours...
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
The introduction in clinical practice of pharmaceutical products known as biosimilars, as part of a more complex series of progress in the field of biological drugs, represents an excellent therapeutic resource. A biosimilar drug is a biological/biotechnological drug that is highly similar to an app...
Enregistré dans:
| Publié dans: | Oncol Ther |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Healthcare
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315076/ https://ncbi.nlm.nih.gov/pubmed/28261647 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-016-0028-9 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|